

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPLICATION NUMBER: 20763**

**CHEMISTRY REVIEW(S)**

DIVISION OF NEUROPHARMACOLOGICAL DRUG PRODUCTS  
Review of Chemistry, Manufacturing, and Controls

NDA#: 20-763

CHEMISTRY REVIEW: # 3

DATE REVIEWED: 20JAN98

<u>Submission Type</u>	<u>Document Date</u>	<u>CDER Date</u>	<u>Assigned Date</u>
ORIGINAL	04DEC96	06DEC96	12DEC96
	four submissions from SEP96 to AUG97: see Reviews #1, 2		
AMENDMENT	17OCT97	20OCT97	21OCT97
AMENDMENT	21NOV97	24NOV97	05JAN98
AMENDMENT	15DEC97	16DEC97	05JAN98
GEN. CORR.	15JAN98	(desk copy)	(not assigned)
GEN. CORR.	16JAN98	(desk copy)	(not assigned)

NAME & ADDRESS OF APPLICANT:

Glaxo Wellcome Inc.  
Five Moore Drive  
Research Triangle Park, NC 27709

DRUG PRODUCT NAME:

Proprietary:

AMERGE™

Nonproprietary/Established/USAN:

naratriptan (hydrochloride) [USAN, 1993]

Code Name/#:


GR85548(A)

Chem. Type/Ther. Class:

1S

DESI / Patent Status:

no DESI issues; patent  
expires August 12,  
2008



PHARMACOLOGICAL CATEGORY/INDICATION:

antimigraine

DOSAGE FORM:

tablets

STRENGTHS:

1.0, 2.5 mg

ROUTE OF ADMINISTRATION:

oral

DISPENSED:

Rx  OTC

CHEMICAL NAME, STRUCTURAL FORMULA,

MOLECULAR FORMULA: structure above right.

IUPAC name: N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide  
monohydrochloride

CAS name: N-methyl-3-(1-methyl-4-piperidinyl)indole-5-ethanesulfonamide monohydrochloride

C<sub>17</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub>S · HCl Mol. Weight: 371.93 CAS #: 143388-64-1 (salt), 121679-13-8 (base)

CONCLUSIONS & RECOMMENDATIONS: See Reviews #1, 2. This review: amendments and  
correspondence on/after 17OCT97. May be approved for chemistry.

cc: Orig. NDA

HFD-120/Division File

HFD-120/DJBates/20JAN98

HFD-120/LChen

HFD-120/MGuzewska/Init. 1.26.98

HFD-810/JSimmons/Init.

HFD-810/CHoiberg/Init.

Doris J. Bates, Ph.D., Review Chemist  
Filename: nararev.003

DIVISION OF NEUROPHARMACOLOGICAL DRUG PRODUCTS  
Review of Chemistry, Manufacturing, and Controls

NDA#: 20-763

CHEMISTRY REVIEW: # 2

DATE REVIEWED: 11SEP97


<u>Submission Type</u>	<u>Document Date</u>	<u>CDER Date</u>	<u>Assigned Date</u>
ORIGINAL	04DEC96	06DEC96	12DEC96
AMENDMENT	06JUN97	09JUN97	09JUN97
GEN. CORR.	10JUN97	not in COMIS	16JUN97
AMENDMENT	20AUG97	21AUG97	21AUG97
GEN. CORR.	04SEP97	05SEP97	08SEP97

NAME & ADDRESS OF APPLICANT: Glaxo Wellcome Inc.  
Five Moore Drive  
Research Triangle Park, NC 27709

DRUG PRODUCT NAME:

Proprietary: AMERGE™ (proposed)  
Nonproprietary/Established/USAN: naratriptan (hydrochloride) [USAN (1993)]  
Code Name/#: GR85548(A)  
Chem. Type/Ther. Class: 1S  
DESI / Patent Status: no DESI issues; patent expires August 12, 2008

PHARMACOLOGICAL CATEGORY/INDICATION: antimigraine  
DOSAGE FORM: tablets  
STRENGTHS: (1.0), 2.5 mg  
ROUTE OF ADMINISTRATION: oral  
DISPENSED: XX Rx       OTC



CHEMICAL NAME, STRUCTURAL FORMULA,  
MOLECULAR FORMULA: structure above right.

N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide hydrochloride;  
C<sub>17</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub>S · HCl    Mol. Weight: 371.93    CAS #: 143388-64-1 (salt), 121679-13-8 (base)

CONCLUSIONS & RECOMMENDATIONS: See Review #1. Methods validation requested, firm has been contacted by labs, validation pending. EER acceptable for all sites as of 11JUN97. First amendment listed above includes stability update for drug substance and drug product. First product stability update is superseded by second amendment which includes cumulative update for product alone, plus answers to questions in FDA letter of 09JUL97. First General Correspondence proposes trade name; acceptable (Nomenclature Committee, 02SEP97.) Second General Correspondence includes electronic version of CMC update. Stability data, responses satisfactory; acceptable validation results anticipated: APPROVE for CMC.

cc: Orig. NDA

HFD-120/Division File  
HFD-120/DJBates/11SEP97  
HFD-120/LChen  
HFD-120/MGuzewska/Init: *11/9.19.97*  
HFD-810/JSimmons/Init:    CHOiberg/Init:

Doris J. Bates, Ph.D., Review Chemist  
Filename: nararev.002